Liquid Nefopam Hydrochloride Market Size, Report by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Liquid Nefopam Hydrochloride Market

5.1. COVID-19 Landscape: Liquid Nefopam Hydrochloride Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Liquid Nefopam Hydrochloride Market, By Formulation

8.1. Liquid Nefopam Hydrochloride Market Revenue and Volume, by Formulation

8.1.1. Injection Ampoules

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Vials

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Prefilled Syringes

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Ready-to-Infuse (RTI) Bags

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Oral Liquid (Hospital Use)

8.1.5.1. Market Revenue and Volume Forecast

Chapter 9. Global Liquid Nefopam Hydrochloride Market, By Concentration

9.1. Liquid Nefopam Hydrochloride Market Revenue and Volume, by Concentration

9.1.1. 20 mg/mL

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. 10 mg/mL

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Other Strengths

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Liquid Nefopam Hydrochloride Market, By Route of Administration

10.1. Liquid Nefopam Hydrochloride Market Revenue and Volume, by Route of Administration

10.1.1. Intravenous (IV)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Intramuscular (IM)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Oral (Adjunct/Bridge)

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Liquid Nefopam Hydrochloride Market, By Indication

11.1. Liquid Nefopam Hydrochloride Market Revenue and Volume, by Indication

11.1.1. Postoperative Acute Pain

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Trauma and Emergency Pain

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Perianesthetic Shivering/Pain Adjunct

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Dental and Minor Procedures

11.1.4.1. Market Revenue and Volume Forecast

11.1.5. Other Hospital Uses

11.1.5.1. Market Revenue and Volume Forecast

Chapter 12. Global Liquid Nefopam Hydrochloride Market, By End-user

12.1. Liquid Nefopam Hydrochloride Market Revenue and Volume, by End-user

12.1.1. Hospitals (Tertiary/Secondary)

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Ambulatory Surgical Centers (ASCs)

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Emergency Medical Services (EMS)

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Specialty Clinics

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Liquid Nefopam Hydrochloride Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Formulation

13.1.2. Market Revenue and Volume Forecast, by Concentration

13.1.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.4. Market Revenue and Volume Forecast, by Indication

13.1.5. Market Revenue and Volume Forecast, by End-user

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Formulation

13.1.6.2. Market Revenue and Volume Forecast, by Concentration

13.1.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.6.4. Market Revenue and Volume Forecast, by Indication

13.1.6.5. Market Revenue and Volume Forecast, by End-user

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Formulation

13.1.7.2. Market Revenue and Volume Forecast, by Concentration

13.1.7.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.7.4. Market Revenue and Volume Forecast, by Indication

13.1.7.5. Market Revenue and Volume Forecast, by End-user

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Formulation

13.2.2. Market Revenue and Volume Forecast, by Concentration

13.2.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.4. Market Revenue and Volume Forecast, by Indication

13.2.5. Market Revenue and Volume Forecast, by End-user

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Formulation

13.2.6.2. Market Revenue and Volume Forecast, by Concentration

13.2.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.7. Market Revenue and Volume Forecast, by Indication

13.2.8. Market Revenue and Volume Forecast, by End-user

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Formulation

13.2.9.2. Market Revenue and Volume Forecast, by Concentration

13.2.9.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.10. Market Revenue and Volume Forecast, by Indication

13.2.11. Market Revenue and Volume Forecast, by End-user

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Formulation

13.2.12.2. Market Revenue and Volume Forecast, by Concentration

13.2.12.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.12.4. Market Revenue and Volume Forecast, by Indication

13.2.13. Market Revenue and Volume Forecast, by End-user

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Formulation

13.2.14.2. Market Revenue and Volume Forecast, by Concentration

13.2.14.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.14.4. Market Revenue and Volume Forecast, by Indication

13.2.15. Market Revenue and Volume Forecast, by End-user

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Formulation

13.3.2. Market Revenue and Volume Forecast, by Concentration

13.3.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.4. Market Revenue and Volume Forecast, by Indication

13.3.5. Market Revenue and Volume Forecast, by End-user

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Formulation

13.3.6.2. Market Revenue and Volume Forecast, by Concentration

13.3.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.6.4. Market Revenue and Volume Forecast, by Indication

13.3.7. Market Revenue and Volume Forecast, by End-user

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Formulation

13.3.8.2. Market Revenue and Volume Forecast, by Concentration

13.3.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.8.4. Market Revenue and Volume Forecast, by Indication

13.3.9. Market Revenue and Volume Forecast, by End-user

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Formulation

13.3.10.2. Market Revenue and Volume Forecast, by Concentration

13.3.10.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.10.4. Market Revenue and Volume Forecast, by Indication

13.3.10.5. Market Revenue and Volume Forecast, by End-user

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Formulation

13.3.11.2. Market Revenue and Volume Forecast, by Concentration

13.3.11.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.11.4. Market Revenue and Volume Forecast, by Indication

13.3.11.5. Market Revenue and Volume Forecast, by End-user

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Formulation

13.4.2. Market Revenue and Volume Forecast, by Concentration

13.4.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.4. Market Revenue and Volume Forecast, by Indication

13.4.5. Market Revenue and Volume Forecast, by End-user

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Formulation

13.4.6.2. Market Revenue and Volume Forecast, by Concentration

13.4.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.6.4. Market Revenue and Volume Forecast, by Indication

13.4.7. Market Revenue and Volume Forecast, by End-user

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Formulation

13.4.8.2. Market Revenue and Volume Forecast, by Concentration

13.4.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.8.4. Market Revenue and Volume Forecast, by Indication

13.4.9. Market Revenue and Volume Forecast, by End-user

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Formulation

13.4.10.2. Market Revenue and Volume Forecast, by Concentration

13.4.10.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.10.4. Market Revenue and Volume Forecast, by Indication

13.4.10.5. Market Revenue and Volume Forecast, by End-user

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Formulation

13.4.11.2. Market Revenue and Volume Forecast, by Concentration

13.4.11.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.11.4. Market Revenue and Volume Forecast, by Indication

13.4.11.5. Market Revenue and Volume Forecast, by End-user

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Formulation

13.5.2. Market Revenue and Volume Forecast, by Concentration

13.5.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.4. Market Revenue and Volume Forecast, by Indication

13.5.5. Market Revenue and Volume Forecast, by End-user

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Formulation

13.5.6.2. Market Revenue and Volume Forecast, by Concentration

13.5.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.6.4. Market Revenue and Volume Forecast, by Indication

13.5.7. Market Revenue and Volume Forecast, by End-user

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Formulation

13.5.8.2. Market Revenue and Volume Forecast, by Concentration

13.5.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.8.4. Market Revenue and Volume Forecast, by Indication

13.5.8.5. Market Revenue and Volume Forecast, by End-user

Chapter 14. Company Profiles

14.1. Paladin Labs

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Biocodex

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Neuraxpharm

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Flynn Pharma

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Viatris (Mylan)

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Teva Pharmaceutical Industries

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Sun Pharmaceutical Industries

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Dr. Reddy’s Laboratories

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Cipla

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Zydus Lifesciences

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The major players in the liquid nefopam hydrochloride market include Biocodex, Neuraxpharm, Flynn Pharma, Paladin Labs, Accord Healthcare, Hikma Pharmaceuticals, Hameln Pharma, Fresenius Kabi, Baxter International, Viatris (Mylan), Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Cipla, Zydus Lifesciences, Lupin, Glenmark Pharmaceuticals, Sandoz, Apotex, and AFT Pharmaceuticals

The driving factors of the liquid nefopam hydrochloride market are growing due to increasing demand for convenient, fast-acting, and easily administrable pain relief formulations.

Europe region will lead the global liquid nefopam hydrochloride market during the forecast period 2025 to 2034.